Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Ibio › Frazier Life Sciences Public Fund, L.P. cut its IBIO stake below 5% (3 Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001231919-26-001582
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Oct 14 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 14 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 14 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Jul 31, 2026 Company filing · Form 8-K · Executive change, Other news Changed a top executive or board member, and reported other company news “Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the “Company”). Dr. Molly Carr, M.D., age 59, is a physician executive with extensive experience in the biotechnology and pharmaceutical industries.” Aug 28, 2026 Company filing · Form 8-K · Results Reported its results What came next Oct 14, 2026 Company filing · Form 8-K · Executive change, Bylaws or charter Changed a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item) “On October 14, 2026, iBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).” Oct 14, 2026 5% stake Coastlands Capital LP reported a passive stake (13G) of 9.7% Nov 10, 2026 Company filing · Form 8-K · Results Reported its results Nov 16, 2026 5% stake Frazier Life Sciences Public Fund, L.P. reported a passive stake (13G) of 3.0% Nov 20, 2026 Company filing · Form 8-K · Listing notice Received a notice from its stock exchange “On November 19, 2026, iBio, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (October 8, 2026 through November 18, 2026), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”), as required…”